Hepatitis Central

The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatments.

New Drug, Actilon, In Development

September 28, 2005

Printer-friendly version

Bookmark and Share

Another new approach in the pipeline. As We've always said, with millions of people infected, the drug and biotech companies are falling over each other to come up with viable treatments to improve on what is currently available.

NEW YORK, Sept 27 (Reuters) - Coley Pharmaceutical Group Inc. (COLY.O: Quote, Profile, Research) on Tuesday said it is starting an early-stage clinical trial of an experimental drug to treat chronic Hepatitis C virus.

Coley expects preliminary data from the Phase Ib study of the drug, Actilon, to be available in the second half of 2006.

The study will involve 60 patients infected with the virus, who will be divided into different treatment groups over a period of three months. Some patients will take only Actilon, some will take it in combination with one or two standard treatments, and some will take standard treatments without Actilon.

The company, which went public last month, has also attracted attention because of three other promising experimental drugs, especially ProMune, which is entering late-stage trials against non-small cell lung cancer. Coley, based in Wellesley, Massachusetts, is developing that product with Pfizer Inc. (PFE.N: Quote, Profile, Research)

Its drugs are designed to stimulate the immune system by acting on proteins called Toll-like receptors. Actilon acts through the Toll-like receptor 9 found in dendritic cells and B cells, which are mainstays of the immune system.

Shares of Coley were up $1.52, or 9.4 percent, to $17.64 on Nasdaq. (Additional reporting by Ransdell Pierson)

Posted by Ralph at September 28, 2005 9:26 AM

Site Topics

  • HCV Symptoms

    You'll find links to a comprehensive symptoms list, as well as various studies and discussions about Hepatitis C symptoms.

  • Lab Tests

    What they are and what they mean. Helps you interpret & understand all the various hepatitis lab tests likely to be encountered.

  • Hepatitis C Genotypes

    Learn about Hepatitis C Genotypes and their variants.

  • Viral Load

    Includes a convenient Viral Load chart, as well as a link to a detailed discussion on how to analyze and interpret viral load numbers.

  • What is...?

    Learn more about various Hepatitis C related topics, including HCV, Ascites, Biopsies, and much more.

  • HCV Medicines

    Numerous links to studies, info sheets, FAQs, and analysis of Ribavirin/Rebetron medicines.

  • Hepatitis C Doctors

    A state-by-state and worldwide reference listing physicians who treat HCV, including an email link to submit your physician for inclusion.

  • Biopsy Info

    A comprehensive resource of information relating to the liver biopsy.

  • Cirrhosis

    Many discussions and analyses of cirrhosis, including causes, complications, pathology, symptoms, and much more.

  • Liver Cancer

    Liver Cancer/Hepatocellular Carcinoma studies, info sheets, FAQs, and analysis.

  • Liver Disease Medicines

    An exhaustive list of links to studies, info sheets, FAQs, and analysis of the various drugs used to treat liver disease.

  • Hep-Central Email List

    Sign up to learn about advances and breakthroughs in Hepatitis C research, including information about medical and complementary treatments.

  • HCV Links

    Convenient links to other sites external to Hepatitis-Central.

  • Mother/Child Transmission

    Discussions of the special problems and precautions necessary involving mother to child transmission of Hepatitis C.

  • HCV Natural Remedies

    A number of herbal products useful in the management of liver disease.

  • HCV Books

    Recommended reading for those interested in hepatitis information.

  • Hepatitis C Forum

    A Bulletin Board for discussions on hepatitis, treatments, etc.

  • Hepatitis C Activism

    An easy way to get involved in urging our government to do more for Hepatitis C awareness and treatment research.

Advertisement

Search R&T News

Advertisement